Skip to main content
SpringerLink
Log in

Contraception in Neurologic and Psychiatric Disorders

  • Chapter
  • First Online:
Neurology and Psychiatry of Women

Abstract

All women of reproductive age with psychiatric and neurologic disease should be screened for contraceptive need, and offered counseling on options compatible with their medications and medical conditions. While non-hormonal methods are appropriate for all patients, hormonal contraception may interact with some medications used by women in treatment of epilepsy, multiple sclerosis and mood disorders. Women at risk for or with a history of stroke should avoid estrogen-containing options; similarly, women who report migraine with aura are also discouraged from use of any estrogen-based contraception due to the potential increase in risk of stroke. Fortunately, the highly effective reversible contraceptive options that include intrauterine devices (IUDs) and the progestin-only implant are appropriate for almost all these women. This chapter provides evidence and guidance for selection of appropriate, safe contraceptive options in women with migraine disease, epilepsy, stroke, multiple sclerosis and psychiatric disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 79.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83:397–404.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Curtis K, Peipert J. Long-acting reversible contraception. N Engl J Med. 2017;376:461–8.

    Article  PubMed  Google Scholar 

  3. Curtis K, Tepper N, Jatlaoui T, Berry-Bibee E, Horton L, Zapata L, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65:1–104.

    PubMed  Google Scholar 

  4. Lipton R, Bigal M. Migraine: epidemiology, impact, and risk factors for progression. Headache. 2005;45:S3–S13.

    Article  PubMed  Google Scholar 

  5. Buse D, Manack A, Fanning K, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52:1456–70.

    Article  PubMed  Google Scholar 

  6. Faubion S, Casey P, Shuster L. Hormonal contraception and migraine: clinical considerations. Curr Pain Headache Rep. 2012;16:461–6.

    Article  PubMed  Google Scholar 

  7. Daniels K, Daugherty J, Jones J, Mosher W. Current contraceptive use and variation by selected characteristics among women aged 15–44: United States, 2011–2013. Natl Health Stat Rep. 2015;86:1–14.

    Google Scholar 

  8. Etminan M, Takkouche B, Isorna F, Samii A. Risks of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ. 2005;330:63.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Tepper N, Whiteman M, Zapata L, Marchbanks P, Curtis K. Safety of hormonal contraceptives among women with migraine: a systematic review. Contraception. 2016;94:630–40.

    Article  CAS  PubMed  Google Scholar 

  10. Fazio G, Ferrara F, Barbaro G, Alessandro G, Ferrro G, Novo G, et al. Prothrombotic effects of contraceptives. Curr Pharm Des. 2010;16:3490–6.

    Article  CAS  PubMed  Google Scholar 

  11. Bousser M, Conard J, Kittner S, de Lignieres B, MacGregor E, Massiou H, et al. Recommendations of the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The International Headache Society Task Force on Combined Oral Contraceptives & Hormone Replacement Therapy. Cephalalgia. 2000;20:155–6.

    Article  CAS  PubMed  Google Scholar 

  12. Lidegaard O, Lokkegaard E, Jensen A, Skovlund C, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366:2257–66.

    Article  CAS  PubMed  Google Scholar 

  13. Champaloux S, Tepper N, Monsour M, Curtis K, Whiteman M, Marchbanks P, et al. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol. 2017;216:489.e1–7.

    Article  CAS  Google Scholar 

  14. Russell M, Rasmussen B, Fenger K, Olesen J. Migraine without aura and migraine with aura are distinct clinical entities: a study of four hundred and eight-four male and female migraineurs from the general population. Cephalalgia. 1996;16:239–45.

    Article  CAS  PubMed  Google Scholar 

  15. Kurth T, Chabriat H, Bousser M. Migraine and stroke: a complex association with clinical implications. Lancet Neurol. 2012;11:92–100.

    Article  PubMed  Google Scholar 

  16. Tepper N, Whiteman M, Marchbanks P, James A, Curtis K. Progestin-only contraception and thromboembolism: a systematic review. Contraception. 2016;94:678–700.

    Article  CAS  PubMed  Google Scholar 

  17. Rosenberg M, Waugh M. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179:577–82.

    Article  CAS  PubMed  Google Scholar 

  18. Loder E, Buse D, Golub J. Headache and combination estrogen-progestin oral contraceptives: integrating evidence, guidelines, and clinical practice. Headache. 2005;45:224–31.

    Article  PubMed  Google Scholar 

  19. Berger G, Edelman D, Talwar P. The probability of side effects with ovral, norinyl 1/50 and norlestrin. Contraception. 1979;20:447–53.

    Article  CAS  PubMed  Google Scholar 

  20. Martin V, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis—part 1. Headache. 2006;46:3–23.

    Article  PubMed  Google Scholar 

  21. Loder E, Rizzoli P, Golub J. Hormonal management of migraine associated with menses and the menopause: a clinical review. Headache. 2007;47:329–40.

    Article  PubMed  Google Scholar 

  22. MacGregor A. Migraine associated with menstruation. Funct Neurol. 2000;15:143–5.

    PubMed  Google Scholar 

  23. Hatcher R, Trussell J, Nelson A, Cates W, Kowal D, Policar M. Contraceptive technology. 20th ed. Atlanta: Bridging the Gap Communications; 2011.

    Google Scholar 

  24. Calhoun A, Ford S, Pruitt A. The impact of extended-cycle vaginal ring contraception on migraine aura: a retrospective case series. Headache. 2012;52:1246–53.

    Article  PubMed  Google Scholar 

  25. Larsson-Cohn U, Lundberg P. Headache and treatment with oral contraceptives. Acta Neurol Scand. 1970;46:267–78.

    Article  CAS  PubMed  Google Scholar 

  26. De Leo V, Scolaro V, Musacchio M, Di Sabatino A, Morgante G, Cianci A. Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril. 2011;96:917–20.

    Article  CAS  PubMed  Google Scholar 

  27. Sulak P, Willis S, Kuehl T, Coffee A, Clark J. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache. 2007;47:27–37.

    PubMed  Google Scholar 

  28. Harden C, Pennell P. Neuroendocrine considerations in the treatment of men and women with epilepsy. Lancet Neurol. 2013;12:72–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Pennell P, Davis A. Selecting contraception for women treated with antiepileptic drugs. In: Klein A, Angela O’Neal M, Scifres C, Waters JFR, Waters JH, editors. Neurological illness in pregnancy: principles and practice. 1st ed: Wiley; 2016. p. 110–21.

    Google Scholar 

  30. Vessey M, Painter R, Yeates D. Oral contraception and epilepsy: findings in a large cohort study. Contraception. 2002;66:77–9.

    Article  PubMed  Google Scholar 

  31. Harden C, Leppik I. Optimizing therapy of seizures in women who use oral contraceptives. Neurology. 2006;67:s56–8.

    Article  CAS  PubMed  Google Scholar 

  32. Herzog A, Mandle H, Cahill K, Fowler K, Houser W. Differential impact of contraceptive methods on seizures varies by anti-epileptic drug category: findings of the epilepsy birth control registry. Epilepsy Behav. 2016;60:112–7.

    Article  PubMed  Google Scholar 

  33. Davis A, Saadatmand H, Pack A. Women with epilepsy initiating a progestin IUD: a prospective pilot study of safety and acceptability. Epilepsia. 2016;57:1143–8.

    Google Scholar 

  34. Dutton C, Foldvary-Shafer N. Contraception in women with epilepsy: pharmacokinetic interactions, contraceptive options and management. Int Rev Neurobiol. 2008;83:113–34.

    Article  PubMed  Google Scholar 

  35. Davis A, Westhoff C, Stanczyk F. Carbamazepine co-administration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation and bleeding. Epilepsia. 2011;52:243–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Lazorwitz A, Swartz M, Davis A, Guihai M. The effect of carbamazepine on etonogestrel concentrations among contraceptive implant users. Contraception. 2016;94:571–7.

    Article  Google Scholar 

  37. Curtis K, Tepper N, Jatlaoui T, Berry-Bibee E, Horton L, Zapata L, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65:48.

    Google Scholar 

  38. U.S. Food and Drug Administration. FDA Drug Safety Communication: updated information about the risk of blood clots in women taking brith control pills containing drospirenone. 2011. Available from: http://www.fda.gov/drugs/drugsafety/ucm299305.htm.

  39. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives: Results of an international, multicenter, case-control study. Contraception. 1998;57:315–24.

    Article  Google Scholar 

  40. Heinemann L, Assmann A, DoMinh T, Garb E. Oral progestogen only contraceptives and cardiovascular risk: results from the transnational study on oral contraceptives and the health of young women. Eur J Contracept Reprod Health Care. 1999;4:67–73.

    Article  CAS  PubMed  Google Scholar 

  41. Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet. 1999;354:1610–1.

    Article  CAS  PubMed  Google Scholar 

  42. Bergendal A, Persson I, Odeberg J, Sundstrom A, Holmstrom M, Schulman S, et al. Obstet Gynecol. 2014;124:600–9.

    Article  CAS  PubMed  Google Scholar 

  43. Mantha S, Karp R, Raghavan V, Terrin N, Bauer K, Zwicker J. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012;345:e4944.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Bove R, Alwan S, Friedman J, Hellwig K, Houtchens M, Koren G, et al. Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet Gynecol. 2014;124:1157–68.

    Article  CAS  PubMed  Google Scholar 

  45. Houtchens M, Kolb C. Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol. 2013;260:1202–4.

    Article  CAS  PubMed  Google Scholar 

  46. Fragoso Y, Adoni T, Alves-Leon S, Azambuja NJ, Barreira A, Brooks J, et al. Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review. CNS Drugs. 2013;27:955–61.

    Article  CAS  PubMed  Google Scholar 

  47. Sahin L, Nallani S, Tassinari M. Medication use in pregnancy and the pregnancy and lactation labeling rule. Clin Pharmacol Ther. 2016;100:23–5.

    Article  CAS  PubMed  Google Scholar 

  48. Vukusic S, Marignier R. Multiple sclerosis and pregnancy in the ‘treatment era. Nat Rev Neurol. 2015;11:280–9.

    Article  PubMed  Google Scholar 

  49. David O, Ocwieja M, Meise K, Emotte C, Jakab A, Wemer J, et al. Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results. Int J Clin Pharmacol Ther. 2012;50:540–4.

    Google Scholar 

  50. Villard-Mackintosh L, Vessey M. Oral contraceptives and reproductive factors in multiple sclerosis incidence. Contraception. 1993;47:161–8.

    Article  CAS  PubMed  Google Scholar 

  51. Thorogood M, Hannaford P. The influence of oral contraceptives on the risk of multiple sclerosis. Br J Obstet Gynecol. 1998;105:1296–9.

    Article  CAS  Google Scholar 

  52. Zapata L, Oduyebo T, Whiteman M, Houtchens M, Marchbanks P, Curtis K. Contraceptive use among women with multiple sclerosis: a systematic review. Contraception. 2016;94:612–20.

    Article  PubMed  Google Scholar 

  53. Kempe P, Hammar M, Brynhildsen J. Symptoms of multiple sclerosis during use of combined hormonal contraception. Eur J Obstet Gynecol Reprod Biol. 2015;19:1–4.

    Article  CAS  Google Scholar 

  54. Westhoff C, Heartwell S, Edwards S, Zieman M, Stuart G, Cwiak C, et al. Oral contraceptive discontinuation: do side effects matter? Am J Obstet Gynecol. 2007;196:412.e1–7.

    Article  CAS  Google Scholar 

  55. Parry B, Rush A. Oral contraceptives and depressive symptomatology: biologic mechanisms. Compr Psychiatry. 1979;20:347–58.

    Article  CAS  PubMed  Google Scholar 

  56. Herzberg B, Johnson A, Brown S. Depressive symptoms and oral contraceptives. Br Med J. 1970;4:142–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Pagano H, Zapata L, Berry-Bibee E, Nanda K, Curtis K. Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review. Contraception. 2016;94(6):641–9.

    Article  CAS  PubMed  Google Scholar 

  58. Keyes K, Cheslack-Postava K, Westhoff C, Heim C, Haloossim M, Walsh K, et al. Association of hormonal contraceptive use with reduced levels of depressive symptoms: a national study of sexually active women in the United States. Am J Epidemiol. 2013;178:1378–88.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Skovlund C, Morch L, Kessing L, Lidegaard O. Association of hormonal contraception with depression. JAMA Psychiat. 2016;73:1154–62.

    Article  Google Scholar 

  60. Skovlund C, Morch L, Kessing L, Lange T, Lidegaard O. Association of hormonal contraception with suicide attempts and suicides. AJP Adv. 2017. https://doi.org/10.1176/appiajp201717060616.

  61. O’Connell K, Davis A, Kerns J. Oral contraceptives: side effects and depression in adolescent girls. Contraception. 2007;75:299–304.

    Article  CAS  PubMed  Google Scholar 

  62. Duke J, Sibbritt D, Young A. Is there an association between the use of oral contraception and depressive symptoms in young Australian women? Contraception. 2007;75:27–31.

    Article  CAS  PubMed  Google Scholar 

  63. Herzberg B, Draper K, Johnson A, Nicol G. Oral contraceptives, depression, and libido. Br Med J. 1971;3:495–500.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Joffe H, Cohen L, Harlow B. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol. 2003;189:1523–30.

    Article  CAS  PubMed  Google Scholar 

  65. Segebladh B, Borgstrom A, Odlind V, Bixo M, Sundstrom-Poromaa I. Prevalence of psychiatric disorders and premenstrual dysphoric symptoms in patients with experience of adverse mood during treatment with combined oral contraceptives. Contraception. 2009;79:50–5.

    Article  CAS  PubMed  Google Scholar 

  66. Bergstrom R, Goldberg M, Cerimele B, Hatcher B. Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clin Pharmacol Ther. 1997;62:643–51.

    Article  CAS  PubMed  Google Scholar 

  67. Chen G, Lee R, Hojer A, Buchbjerg J, Serenko M, Zhao Z. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013;33:727–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Koke S, Brown E, Miner C. Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy. Obstet Gynecol. 2002;187:551–5.

    CAS  Google Scholar 

  69. Kornstein S, Toups M, Rush A, Wisniewski S, Thase M, Luther J, et al. Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the sequenced treatment alternatives to relieve depression (STAR*D) study. J Women's Health. 2013;22:121–31.

    Article  Google Scholar 

  70. Beaumont G. Drug interactions with clomipramine (Anafranil). J Int Med Res. 1973;1:480–4.

    Article  Google Scholar 

  71. Gringras M, Beaumont G, Grieve A. Clomipramine and oral contraceptives: an interaction study–clinical findings. J Int Med Res. 1980;8:76–80.

    PubMed  Google Scholar 

  72. Abernethy D, Greenblatt D, Shader R. Imipramine disposition in users of oral contraceptive steroids. Clin Pharmacol Ther. 1984;35:792–7.

    Article  CAS  PubMed  Google Scholar 

  73. Edelbroek P, Zitman F, Knoppert-van der Klein E, van Putten P, de Wolff F. Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women. Clin Chim Acta. 1987;165:177–87.

    Article  CAS  PubMed  Google Scholar 

  74. Berry-Bibee E, Kim M, Simmons K, Tepper N, Riley H, Pagano H, et al. Drug interactions between hormonal contraceptives and psychotropic drugs: a systematic review. Contraception. 2016;94:650–67.

    Article  CAS  PubMed  Google Scholar 

  75. Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, Laine K. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2003;74:326–33.

    Article  CAS  PubMed  Google Scholar 

  76. Edelman A, Micks E, Gallo M, Jensen J, Grimes D. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev. 2014;7:CD004695.

    Google Scholar 

  77. Lopez L, Kaptein A, Helmerhorst F. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2012;2:CD006586.

    Google Scholar 

  78. Freeman E, Halbreich U, Grubb G, Rapkin A, Skouby S, Smith L, et al. An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception. 2012;85(5):437–45.

    Article  CAS  PubMed  Google Scholar 

  79. Berenson A, Asem H, Tan A, Wilkinson G. Continuation rates and complications of intrauterine contraception in women diagnosed with bipolar disorder. Obstet Gynecol. 2011;118:1331–6.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Rasgon N, Bauer M, Glenn T, Elman S, Whybrow P. Menstrual cycle related mood changes in women with bipolar disorder. Bipolar Disord. 2003;5:48–52.

    Article  PubMed  Google Scholar 

  81. Chiu Y, Ereshefsky L, Preskorn S, Poola N, Loebel A. Lurasidone drug–drug interaction studies: a comprehensive review. Drug Metabol Drug Interact. 2014;29:191–202.

    Article  CAS  PubMed  Google Scholar 

  82. Muirhead G, Harness J, Holt P, Oliver S, Anziano R. Ziprasidone and the pharmacokinetics of a combined oral contraceptive. Clin Pharmacol. 2000;49:49S–56S.

    Article  CAS  Google Scholar 

  83. Haslemo T, Refsum H, Molden E. The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine. Clin Pharmacol. 2011;71:611–6155.

    Article  CAS  Google Scholar 

  84. Garbers S, Correa N, Tobier N, Blust S, Chiasson M. Association between symptoms of depression and contraceptive method choices among low-income women at urban reproductive health centers. Matern Child Health J. 2010;14:102–9.

    Article  PubMed  Google Scholar 

  85. Hall K, White K, Rickert V, Reame N, Westhoff C. Influence of depressed mood and psychological stress symptoms on perceived oral contraceptive side effects and discontinuation in young minority women. Contraception. 2012;86:518–25.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Callegari L, Zhao X, Nelson K, Borerro S. Contraceptive adherence among women veterans with mental illness and substance use disorder. Contraception. 2015;91:386–92.

    Article  PubMed  Google Scholar 

  87. American College of Obstetricians and Gynecologists. Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. ACOG Committee Opinion No. 450. Obstet Gynecol. 2009;14:1434–8.

    Google Scholar 

  88. Ott M, Sucato G. Contraception for adolescents. Pediatrics. 2014;134:e1244–5.

    Article  Google Scholar 

  89. Davis A, Pack A, Dennis A. Contraception for women with epilepsy. In: Allen RH, Cwiak C, editors. Contraception for the medically challenging patient. New York: Springer Science+Business Media; 2014.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Brigham and Women’s Hospital, Boston, MA, USA

    Caryn Dutton & Deborah Bartz

  2. Harvard Medical School, Boston, MA, USA

    Caryn Dutton & Deborah Bartz

  3. Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

    Andrea Hsu Roe

  4. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Andrea Hsu Roe

Authors
  1. Caryn Dutton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Hsu Roe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Deborah Bartz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caryn Dutton .

Editor information

Editors and Affiliations

  1. Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA

    Mary Angela O’Neal

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Dutton, C., Roe, A.H., Bartz, D. (2019). Contraception in Neurologic and Psychiatric Disorders. In: O’Neal, M. (eds) Neurology and Psychiatry of Women. Springer, Cham. https://doi.org/10.1007/978-3-030-04245-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-04245-5_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-04244-8

  • Online ISBN: 978-3-030-04245-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation